



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553
Laboratory Director : Robert M David, Ph.D

PATIENT DEMOGRAPHICS	Patient Name: Joyce Ferguson	Account: Premier Mountain Healthcare	Order Code: NE22-0007284
	DOB: 02/25/1939	Provider: Leon Driss	Sample Type: Urine
	Patient Gender: F	Accession: 22040800048	Collected: 04/05/2022
	Patient Phone Number:	Report Status: FINAL	Received: 2022-04-08T13:48:52.635979
			Reported: 04/13/2022

PRESCRIPTION LIST	Lisinopril (Prinivil , Zestril) , Atorvastatin (Lipitor) , Empagliflozin (Jardiance) , Triamcinolone (Aristocort) , Diclofenac (Flector , Cambia , Zorvolex , Voltaren) , Letrozole (Femara) , Ibandronate (oral/injection) (Boniva , Bondronat)	DIAGNOSIS CODES	Z51.81, Z79.899, E11.9 Type 2 diabetes mellitus without complications, I10 Hypertension
----------------------	--	--------------------	---

INCONSISTENT			
NOT PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
NSAID	Salicylic Acid	400	14452.35
Metabolite of Acetylsalicylic Acid			
[DDI] Salicylic acid may increase the hypoglycemic activities of Empagliflozin.			
[DDI] The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Salicylic acid.			
STIMULANT	Caffeine	50	> 2500
[DDI] The metabolism of Diclofenac can be decreased when combined with Caffeine.			

INCONSISTENT			
PRESCRIBED		NOT DETECTED	
Class	Test	Cutoff (ng/mL)	
NSAID	Diclofenac	50	
[DDI] Diclofenac may decrease the excretion rate of Atorvastatin which could result in a higher serum level.			
[DDI] The risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylic acid.			
[DDI] The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Diclofenac.			
NSAID	4-Hydroxydiclofenac	50	
Metabolite of Diclofenac			

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Triamcinolone	[DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Letrozole. [DDI] The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.	

CONSISTENT			
PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
CARDIOVASCULAR	Lisinopril	50	693.00
[DDI] The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.			
STATIN	Atorvastatin	10	74.20
[DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin.			
[DDI] The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Atorvastatin.			

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	4.9
Specific Gravity	1.01 - 1.03	1.01
Urine Creatinine (mg/dL)	20.00 - 400.00	26.47



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Robert M David, Ph.D

PATIENT	Patient Name: Joyce Ferguson	Account: Premier Mountain Healthcare	Order Code: NE22-0007284
DEMOGRAPHICS	DOB: 02/25/1939	Provider: Leon Driss	Sample Type: Urine
	Patient Gender: F	Accession: 22040800048	Collected: 04/05/2022
	Patient Phone Number:	Report Status: FINAL	Received: 2022-04-08T13:48:52.635979
			Reported: 04/13/2022

NOT PRESCRIBED								NOT DETECTED	
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
4-Hydroxydiclofenac	50	Apixaban	25	Haloperidol	25	Norfentanyl	8	Sumatriptan	50
6-MAM	25	Aripiprazole	20	Hydrochlorothiazide	50	Norhydrocodone	50	Tapentadol	50
7-Aminoclonazepam	40	Atenolol	50	Hydrocodone	50	Norketamine	10	Temazepam	40
Carboxyibuprofen	400	Atomoxetine	50	Hydromorphone	50	Normeperidine	100	THC-COOH	50
Digoxin	10	Baclofen	50	Hydroxybupropion	50	Noroxycodone	50	Topiramate	50
Ethyl Glucuronide	500	Benzoylcegonine	50	Imipramine	50	Norpropoxyphene	100	Tramadol	100
Ethyl Sulfate	200	Buprenorphine	10	Indomethacin	50	Nortriptyline	50	Trazodone	50
MDMA	100	Buspirone	50	Irbesartan	50	Norverapamil	50	Valsartan	50
Metformin	500	Butalbital	100	Levetiracetam	50	O-Desmethyltramadol	100	Venlafaxine	100
Sertraline	50	Carbamazepine	50	Lorazepam	40	O-Desmethylvenlafaxine	100	Warfarin	10
Sitagliptin	50	Carbamazepine Epoxide	50	Lurasidone	25	Olanzapine	25	Zaleplon	10
Codeine	50	Carboxycyclogrel	50	MDA	100	Oxazepam	40	Ziprasidone	25
Cotinine	50	Carboxyzolpidem	50	Meprobamate	200	Oxycodone	50	Zolmitriptan	50
Cyclobenzaprine	50	Carisoprodol	100	Methadone	100	Oxymorphone	50		
Dehydroaripiprazole	20	Celecoxib	50	Methamphetamine	100	Paroxetine	25		
Desalkylflurazepam	40	Chlorpromazine	25	Methotrexate	50	Phencyclidine	10		
Desipramine	50	Clonazepam	20	Metoprolol	50	Phenobarbital	100		
Dextrorphan	25	Clonidine	50	Mitragynine	25	Phentermine	100		
Diazepam	10	Diltiazem	50	Morphine	50	Pioglitazone	50		
Dihydrocodeine	50	Diphenhydramine	50	Mycophenolic acid	50	Pitavastatin	10		
7-Aminoflunitrazepam	40	Donepezil	50	Naloxone	10	Pregabalin	150		
9-Hydroxyrisperidone	10	Doxepin	30	Naltrexone	10	Propranolol	50		
Acetaminophen	400	Duloxetine	50	Naproxen	100	Protriptyline	50		
a-Hydroxymidazolam	30	EDDP	100	N-Desmethylocitalopram	50	Pseudoephedrine	50		
a-Hydroxytriazolam	30	Fentanyl	2	N-Desmethyloclozapine	25	Quetiapine	50		
alpha-Hydroxyalprazolam	30	Fluoxetine	25	N-Desmethylmirtazapine	25	Risperidone	10		
Alprazolam	30	Furosemide	50	N-Desmethyloanzapine	25	Ritalinic Acid	50		
Amitriptyline	50	Gabapentin	1000	N-Desmethyltapentadol	50	Rivaroxaban	50		
Amlodipine	25	Glipizide	10	Norbuprenorphine	30	Rosuvastatin	20		
Amphetamine	200	Glyburide	10	Nordiazepam	40	Sufentanil	5		

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.